Sanofi pays Scribe $25M to access CRISPR tools, writing new chapter in its NK cell therapy story
Fierce Biotech
|
September 27, 2022
X min read
Fierce Biotech
|
September 27, 2022
Share on Social
More like this
News
Scribe Therapeutics Highlights Latest Data on Lp(a)-Lowering Therapy and Novel AI Platform for Next-Generation CRISPR-Based Therapeutics at Two Premier Conferences
September 9, 2025
Read Now
Press
Scribe Therapeutics Highlights Latest Data on Lp(a)-Lowering Therapy and Novel AI Platform for Next-Generation CRISPR-Based Therapeutics at Two Premier Conferences
September 9, 2025
Read Now
News
Scribe Therapeutics to Demonstrate Scientific and Corporate Leadership at Upcoming Conferences
August 25, 2025
Read Now
Press
Scribe Therapeutics to Demonstrate Scientific and Corporate Leadership at Upcoming Conferences
August 25, 2025
Read Now
News
Scribe Therapeutics Reports Positive Preclinical Data on its Novel CRISPR Technologies at the 2025 EAS Congress and ASGCT Annual Meeting
May 22, 2025
Read Now
Press
Scribe Therapeutics Reports Positive Preclinical Data on its Novel CRISPR Technologies at the 2025 EAS Congress and ASGCT Annual Meeting
May 22, 2025
Read Now
